For diagnostic pathology, identifying TP53 status in ovarian carcinoma has critical clinical utility: distinguishing HGSOC from low‐grade serous carcinoma on small tissue biopsies before commencing neoadjuvant chemotherapy 10, identification of STIC 49 and sub‐classification of ovarian carcinomas for inclusion in histotype‐specific clinical trials 19. This evidence concerns the gene TP53 and serous adenocarcinoma.